Last updated: February 14, 2024
Sponsor: Biotronik AG
Overall Status: Terminated
Phase
N/A
Condition
Coronary Artery Disease
Myocardial Ischemia
Atherosclerosis
Treatment
Orsiro Sirolimus Eluting Coronary Stent System
Clinical Study ID
NCT03600948
C1607
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Subjects ≥18 years of Age
- Subject must sign a Patient Informed Consent (PIC)
- Subject must agree to undergo all required follow-up visits, either at the hospital orby phone.
- Subject with coronary artery disease requiring treatment with Orsiro Sirolimus elutingstent system
Exclusion
Exclusion Criteria:
- Pregnant and/or breast feeding females at the time of enrolment
- Known allergies to Acetylsalicylic Acid (ASA), clopidogrel, ticlopidine, heparin orany other anticoagulant /antiplatelet required for PCI, contrast medium, sirolimus, orsimilar drugs, or the stent materials that cannot be adequately pre-medicated
- Currently participating in another study that has not yet reached the primaryendpoint.
Study Design
Total Participants: 261
Treatment Group(s): 1
Primary Treatment: Orsiro Sirolimus Eluting Coronary Stent System
Phase:
Study Start date:
August 27, 2018
Estimated Completion Date:
October 06, 2021
Study Description
Connect with a study center
Moinhos de Vento Hospital
Porto Alegre, 90560-030
BrazilSite Not Available
Hospital de Base
São José do Rio Preto,
BrazilSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.